B. Riley Raises Arrowhead Pharmaceuticals (ARWR) Price Target to $4.00
Arrowhead Pharmaceuticals (NASDAQ:ARWR) had its target price upped by analysts at B. Riley from $3.00 to $4.00 in a research report issued on Monday. The firm presently has a “neutral” rating on the biotechnology company’s stock. B. Riley’s price target would indicate a potential downside of 28.44% from the stock’s current price.
A number of other analysts also recently commented on the company. Cantor Fitzgerald set a $5.00 price objective on Arrowhead Pharmaceuticals and gave the stock a “hold” rating in a research report on Monday. ValuEngine upgraded Arrowhead Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, February 2nd. Chardan Capital reiterated a “neutral” rating on shares of Arrowhead Pharmaceuticals in a research report on Tuesday, January 16th. BidaskClub upgraded Arrowhead Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a research report on Thursday, January 18th. Finally, Piper Jaffray Companies upgraded Arrowhead Pharmaceuticals from a “neutral” rating to an “overweight” rating and set a $5.50 price objective for the company in a research report on Monday, November 27th. Five investment analysts have rated the stock with a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has an average rating of “Buy” and an average price target of $4.13.
Shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) opened at $5.59 on Monday. The company has a quick ratio of 3.63, a current ratio of 3.63 and a debt-to-equity ratio of 0.03. Arrowhead Pharmaceuticals has a 52-week low of $1.42 and a 52-week high of $6.75. The company has a market capitalization of $485.14, a P/E ratio of -11.89 and a beta of 2.53.
In related news, COO Bruce D. Given sold 20,000 shares of the firm’s stock in a transaction that occurred on Monday, January 1st. The stock was sold at an average price of $3.69, for a total transaction of $73,800.00. Following the completion of the transaction, the chief operating officer now owns 948,356 shares in the company, valued at approximately $3,499,433.64. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. 4.60% of the stock is owned by company insiders.
Several institutional investors have recently bought and sold shares of ARWR. First Manhattan Co. bought a new position in shares of Arrowhead Pharmaceuticals during the 4th quarter worth approximately $11,707,000. ING Groep NV bought a new position in shares of Arrowhead Pharmaceuticals during the 3rd quarter worth approximately $3,500,000. Allianz Asset Management GmbH bought a new position in shares of Arrowhead Pharmaceuticals during the 3rd quarter worth approximately $1,958,000. Alps Advisors Inc. bought a new position in shares of Arrowhead Pharmaceuticals during the 4th quarter worth approximately $305,000. Finally, Acadian Asset Management LLC lifted its position in shares of Arrowhead Pharmaceuticals by 1,177.7% during the 4th quarter. Acadian Asset Management LLC now owns 71,664 shares of the biotechnology company’s stock worth $264,000 after buying an additional 66,055 shares during the period. Institutional investors and hedge funds own 20.48% of the company’s stock.
Arrowhead Pharmaceuticals Company Profile
Arrowhead Pharmaceuticals, Inc, formerly Arrowhead Research Corporation, develops medicines that treat intractable diseases by silencing the genes that cause them. Using a portfolio of ribonucleic acid (RNA) chemistries and modes of delivery, the Company’s therapies trigger the RNA interference mechanism to induce knockdown of target genes.
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.